The antithrombotic effect of angiotensin-(1-7) involves Mas-mediated NO release from platelets

Molecular Medicine

Volumn 14, Issue 1-2, 2008, Pages 28-35

  Fraga Silva, Rodrigo Araújo ^a   Pinheiro, Sergio Veloso Brant ^a   Gonçalves, Andrey Christian Costa ^b   Alenina, Nathalia ^b   Bader, Michael ^b   Souza Dos Santos, Robson Augusto ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; NITRIC OXIDE; 7 ALA ANGIOTENSIN (1 7); 7-ALA-ANGIOTENSIN (1-7); ANGIOTENSIN I; ANGIOTENSIN I (1 7); ANGIOTENSIN I (1-7); ANGIOTENSIN II; DRUG DERIVATIVE; G PROTEIN COUPLED RECEPTOR; ONCOPROTEIN; PEPTIDE FRAGMENT; PROTO ONCOGENE PROTEINS C MAS 1; PROTO-ONCOGENE PROTEINS C-MAS-1; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLEEDING; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ELECTROPHORESIS; HEMOSTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOGENESIS; WESTERN BLOTTING; ANIMAL; BLEEDING TIME; BLOOD CLOTTING; C57BL MOUSE; DRUG EFFECT; METABOLISM; MOUSE MUTANT; RAT; SECRETION;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; BLEEDING TIME; BLOOD COAGULATION; BLOOD PLATELETS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RATS; RECEPTORS, G-PROTEIN-COUPLED; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 40349087454     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2007-00073.Fraga-Silva     Document Type: Article

References (26)

1. Lip GY, Edmunds E, Beevers DG. Should patients with hypertension receive antithrombotic therapy? J. Intern. Med. 2001;249(3):205-14.
2. Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur. J. Cardiovasc. Nurs. 2002;1:273-88.
3. Packham MA. Role of platelets in thrombosis and hemostasis. Can. J. Physiol. Pharmacol. 1994;72:278-84.
4. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 2001;88:756-62.
5. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993;87:1816-28.
6. Kucharewicz I, Pawlak R, Matys T, et al. Angiotensin-(1-7): an active member of the renin-angiotensin system. J. Physiol. Pharmacol. 2002;53(4 Pt 1):533-40.
7. Nishimura H, Tsuji H, Masuda H, et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb. Haemost. 1997;77:1189-95.
8. van Leeuwen RT, Kol A, Andreotti F, et al. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994;90:362-8.
9. Moore TJ, Williams GH. Angiotensin II receptors on human platelets. Circ. Res. 1982;51:314-20.
10. Jagroop IA, Mikhailidis DP. Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J. Hum. Hypertens. 2000;14:581-5.
11. Kalinowski L, Matys T, Chabielska E, et al. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002;40:521-7.
12. Ferrario CM, Chappell MC, Tallant EA, et al. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997;30(3 Pt 2):535-41.
13. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U S A. 2003;100:8258-63.
14. Kucharewicz I, Pawlak R, Matys T, et al. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension 2002;40:774-9.
15. Kucharewicz I, Chabielska E, Pawlak D, et al. The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan. J. Renin Angiotensin Aldosterone Syst. 2000;1:268-72.
16. Heitsch H, Brovkovych S, Malinski T, et al. Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension 2001;37:72-6.
17. Pinheiro SV, Simoes e Silva AC, Sampaio WO, et al. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 2004;44:490-6.
18. Sampaio WO, Souza dos Santos RA, Faria-Silva R, et al. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007;49:185-92.
19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976;72:248-54.
20. Jantzen HM, Milstone DS, Gousset L, et al. Impaired activation of murine platelets lacking G alpha(i2). J. Clin. Invest. 2001;108:477-83.
21. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb. Res. 1990;60:269-80.
22. Holland JM. Serotonin deficiency and prolonged bleeding in beige mice. Proc. Soc. Exp. Biol. Med. 1976;151:32-9.
23. Rajendran S, Chirkov YY, Campbell DJ, et al. Angiotensin-(1-7) enhances anti-aggregatory effects of the nitric oxide donor sodium nitroprusside. J. Cardiovasc. Pharmacol. Oct 2005;46(4):459-63.
24. Randriamboavonjy V, Fleming I. Endothelial nitric oxide synthase (eNOS) in platelets: how is it regulated and what is it doing there? Pharmacol. Rep. 2005;57 Suppl:59-65.
25. Balcerczyk A, Soszynski M, Bartosz G. On the specificity of 4-amino-5-methylamino-2′,7′-difluorofluorescein as a probe for nitric oxide. Free Radic. Biol. Med. 2005;39(3):327-35.
26. Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. Regul. Pept. 2000;91:45-62.